Compare DexCom, Inc. (DXCM) vs Hewlett Packard Enterprise Co (HPE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Hewlett Packard Enterprise Co — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while Hewlett Packard Enterprise Co trades at $73.46 (market cap $94.25B). The key difference: Hewlett Packard Enterprise Co is far larger — about 3× DexCom, Inc.'s market cap, and Hewlett Packard Enterprise Co pays a 0.8% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Hewlett Packard Enterprise Co for 33 Days on average.
| DXCM | HPE | |
|---|---|---|
Market Cap | $31.86B | $94.25B |
Volume | 3,607,070 | 16,060,854 |
Sector | Health | Technology |
52-Week High | $92.34 | $73.46 |
52-Week Low | $54.84 | $20.01 |
Typical Hold Time | 62 Days | 33 Days |
Enterprise Value | $31.32B | $108.28B |
Dividend Yield | — | 0.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth from $2.9B in 2022 to $4.66B in 2025. Profit margins have expanded significantly to 17.93%, while analyst sentiment remains overwhelmingly positive with 81% buy ratings. Recent news highlights the company's focus on Type 2 diabetes market expansion and leadership appointments.
DXCM presents a compelling growth story with expanding profitability and market opportunities, though elevated valuation multiples and technical bearish signals warrant caution. The consensus price target of $95.07 suggests 13% upside potential, but investors should monitor competitive pressures and reimbursement challenges in the CGM market.
Hewlett Packard Enterprise (HPE) trades at $70.99, down 1.56% today but near its 52-week high following strong AI-driven momentum. The stock has gained over 160% year-over-year, supported by recent earnings beats and a $1.2 billion AI infrastructure order from Vultr. Technical indicators show bullish moving averages but overbought RSI levels, while fundamentals reveal robust revenue growth projections to $41.9 billion in 2026 despite margin compression in 2025.
HPE presents a compelling growth story fueled by AI infrastructure demand, with analyst consensus leaning bullish (47.5% Buy ratings) and a $70.35 price target. Key risks include elevated valuation multiples (P/E 36.6) and execution challenges in integrating Juniper Networks, but raised guidance and institutional upgrades signal confidence in near-term upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Hewlett Packard Enterprise Co
Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment.
Read more on HPE →
